Laekna raises $100M in Hong Kong IPO, while Merck-partnered Kelun seeks up to $208M

A pair of Chinese biotechs with Big Pharma ties is bringing some fresh IPO activity to the biotech corner of Hong Kong’s stock exchange after a lull.

Shanghai-based Laekna has raised just over $100 million to develop its cancer and fibrosis drugs, including two lead candidates licensed from Novartis, while…
Click here to view original post